These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36856291)

  • 1. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint.
    Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM
    J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
    Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
    Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
    Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT
    Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.
    Sun S; van la Parra RFD; Rauch GM; Checka C; Tadros AB; Lucci A; Teshome M; Black D; Hwang RF; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
    Ann Surg Oncol; 2019 Oct; 26(10):3071-3079. PubMed ID: 31342361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
    van der Noordaa MEM; van Duijnhoven FH; Loo CE; van Werkhoven E; van de Vijver KK; Wiersma T; Winter-Warnars HAO; Sonke GS; Vrancken Peeters MTFD
    Breast; 2018 Aug; 40():76-81. PubMed ID: 29698928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy.
    Tasoulis MK; Muktar S; Smith I; Roche N; MacNeill F
    Eur J Surg Oncol; 2024 Jun; 50(6):108277. PubMed ID: 38522333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial.
    van Hemert AKE; van Duijnhoven FH; van Loevezijn AA; Loo CE; Wiersma T; Groen EJ; Peeters MTFDV
    Ann Surg Oncol; 2023 Aug; 30(8):4682-4689. PubMed ID: 37071235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
    Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
    Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    Pfob A; Sidey-Gibbons C; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten M; Golatta M; Heil J
    J Clin Oncol; 2022 Jun; 40(17):1903-1915. PubMed ID: 35108029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
    van Loevezijn AA; van der Noordaa MEM; van Werkhoven ED; Loo CE; Winter-Warnars GAO; Wiersma T; van de Vijver KK; Groen EJ; Blanken-Peeters CFJM; Zonneveld BJGL; Sonke GS; van Duijnhoven FH; Vrancken Peeters MTFD
    Ann Surg Oncol; 2021 Jun; 28(6):3243-3253. PubMed ID: 33263830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
    Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
    Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
    Downs-Canner S; Weiss A
    Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
    Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
    A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
    O'Sullivan CC; Ballman KV; McCall L; Kommalapati A; Zemla T; Weiss A; Mitchell M; Blinder V; Tung NM; Irvin WJ; Lee M; Goetz MP; Symmans WF; Borges VF; Krop I; Carey LA; Partridge AH
    Future Oncol; 2021 Dec; 17(34):4665-4676. PubMed ID: 34636255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial.
    Johnson HM; Lin H; Shen Y; Diego EJ; Krishnamurthy S; Yang WT; Smith BD; Valero V; Lucci A; Sun SX; Shaitelman SF; Mitchell MP; Boughey JC; White RL; Rauch GM; Kuerer HM;
    JAMA Netw Open; 2023 Sep; 6(9):e2333933. PubMed ID: 37707811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
    Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.